Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

NCT07782359 · Not yet recruiting

Last updated 2026-08-27

This clinical trial is testing whether a GLP1 medication can help reduce treatment-related side effects, such as weight loss, in lung cancer patients taking lorlatinib.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 30 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-10 · est. completion 2030-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07782359 ↗

Description as written by the study sponsor.

The proposed study seeks to address a critical gap in the management of lorlatinib-induced metabolic derangements, particularly rapid weight gain, which can adversely affect treatment adherence, dosing and ultimately patient outcomes. In this study patients with non-small cell lung cancer (NSCLC) receiving lorlatinib treatment will receive tirzepatide, a dual GIP/GLP-1 receptor agonist with demonstrated efficacy in weight reduction and metabolic improvement. This study seeks to evaluate its potential to mitigate side effects while preserving the therapeutic efficacy of lorlatinib.

Treatments tested

Tirzepatide also known as Monjouro, Zepbound Drug

Participants will receive tirzepatide with weekly subcutaneous injections at 2.5 mg, following a structured dose escalation protocol over 20 weeks to reach the target dose of 15 mg per week or the maximum tolerated dose.

Main thing measured	Body weight changes
Sponsor	University of Chicago
Conditions studied	Lung Cancer
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07782359 ↗